Although Inetetamab exhibits notable efficacy in the treatment of breast cancer, its clinical application is constrained by potential cardiotoxic side effects that are similar to trastuzumab, the pioneering monoclonal antibody targeting HER2. Here, ERBB2 is linked to breast cancer.